RxDoctor Payments Data

Brent Kleier

Gerontology · Louisville, KYNPI 1689342974

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 29.0% of the total.

$2,173in general payments, 2019–2025

Across 123 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$630
  • Takeda Pharmaceuticals U.S.A., Inc.$277
  • Ardelyx, Inc.$258
  • Johnson & Johnson$207
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$170
  • Phathom Pharmaceuticals, Inc.$126
  • plus $506 from 11 others

What the payments were for

  • Food & beverage$2,09696%
  • Education$774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,173 in reported general payments places this provider in the 75th percentile of 84 gerontology providers in Kentucky.

See all gerontology providers in Kentucky

Medicare billing

Part B allowed, 2024
$16,026
Medicare patients
124
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab20$543,252
Humira(Cf) PenAdalimumab11$153,067
LinzessLinaclotide17$13,117
CholestyramineCholestyramine (With Sugar)19$1,536
Pantoprazole Sodium41$541
Promethazine Hcl21$463
Esomeprazole Magnesium14$445
Budesonide DrBudesonide12$391
Dicyclomine Hcl22$377
Ondansetron Hcl14$295
Famotidine13$135
Omeprazole16$110
Rabeprazole Sodium11$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$207$543,25220 claims
AbbVieLinzess$630$13,11717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 84 gerontology providers in Kentucky.

Other gerontology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →